Inve India ▾

Healthcare Global Enterprises share price & results

Healthcare Global Enterprises Limited· Healthcare

Results to
Jun 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

Pan-India oncology hospital chain operating comprehensive cancer centres across India and Kenya.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue695 ₹ crore+13.4% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin18.0 %0.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit16.0 ₹ crore+166.7% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity4.08 %−2.6 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin2.32 %−2.6 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)13.67 %−1.8 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

6 of 8 judged targets kept · 12 open · verdicts reflect calls analysed to Q1 FY27.

Healthcare Global Enterprises Limited management guidance track record on Inve: 20 targets tracked across analysed earnings calls (6 achieved, 2 missed, 12 open).

TargetOriginal wordingSaidLatest callVerdict
Adjusted EBITDA margin expansion vs FY25 in FY26Margin to expand ~1% to 1.5% in the next financial year vs FY25
Call transcript, Q3 FY25 · 6 Mar 2025		Q3 FY25Q1 FY27:FY26 outcome is closed and unchanged at +70 bps. Q1 FY27 margin of 19.4% (+120 bps YoY) is tracked under the FY27 promise.
Call transcript, Q1 FY27 · 7 Aug 2026		Achieved*
Realization growth (ARPOB, later ARPP)ARPOB to increase 7-8% in FY26
Call transcript, Q4 FY25 · 26 May 2025		Q4 FY25Q1 FY27:The FY26 target is closed as missed. Q1 FY27 ARPP grew just +2%, further below the original 7-8% and the 5% used in the growth bridge. Part of the drag is the deliberate exit of high-value chemo drugs. ARPOB is still not reported.
Call transcript, Q1 FY27 · 7 Aug 2026		Missed
International/medical tourism share of revenueMaintain international contribution at 3.5-4% of revenue; Q4 FY25 recovery to Q2 level
Call transcript, Q3 FY25 · 6 Mar 2025		Q3 FY25Q1 FY27:No international share or Kenya data in Q1 FY27 disclosures. The FY30 deadline is distant, so this is not ghosted. No evidence of improvement, and West cluster growth was only 9%.
Call transcript, Q1 FY27 · 7 Aug 2026		At Risk

Source: Inve Guidance Tracker for Healthcare Global Enterprises Limited · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

2 of Healthcare Global Enterprises Limited's 20 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 17 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹569.85 +3.68% · +₹20.2

Last close 26 Oct 2026 · NSE · INR · Source: Inve

Performance −24.9% 1Y

₹600₹700Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q2 FY26 — 4 Dec 2025Q3 FY26 — 9 Feb 2026Q4 FY26 — 26 May 2026Q1 FY27 — 7 Aug 2026

1Y: ₹759.1 on 24 Oct 2025 → ₹569.85. High ₹776.3 (29 Oct 2025), low ₹521.75 (23 Mar 2026).

Previous close
₹549.65
Market cap
₹8.5k Cr
52-week range
₹521.75 – ₹776.3
One year
−20.95%
Price to earnings (TTM to Jun 2026)
184.96×
Return on equity (TTM to Jun 2026)
4.08%

Overview

Symbol
NSE:HCG
Exchange
NSE
Currency
INR

What Healthcare Global Enterprises Limited does

Based on the company's own presentations, annual report and earnings calls.

HealthCare Global Enterprises (HCG) runs a network of comprehensive cancer centres and dedicated infusion facilities offering diagnosis and treatment across medical oncology, radiation oncology, surgical oncology and outpatient oncology services, alongside select non-oncology specialties. Hospitals are organised into South, West and East regional clusters in India plus an international business in Kenya, treating patients under a mix of cash/TPA and government payor arrangements. The company has been adding capacity through greenfield and brownfield hospital expansions and recently introduced MR-Linac and theranostics capabilities. In FY26 HCG divested its non-core fertility business (Milann) to sharpen focus on its core oncology platform.

Segments

  • South Cluster
  • West Cluster
  • East Cluster
  • International
Hospitals / Comprehensive Cancer Centres
25
Cities / states covered (India)
19 cities across 10 states, plus Kenya
Installed bed capacity
2,600+
Linear accelerators (LINACs) for radiation therapy
38
Operation theatres
100
Clinical modalities offered
Medical oncology, radiation oncology, surgical oncology, outpatient oncology services, non-oncology specialties
Founded 1998Headquarters Bengaluru, Karnataka, India Company website

How the price took the results

close before → close after

Q1 FY27
−0.4%
7 Aug
Q4 FY26
+0.0%
26 May
Q3 FY26
−1.3%
9 Feb
Q2 FY26
−0.3%
4 Dec

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Healthcare Global Enterprises Limited

Free account: one company. Everything above stays public.

Write why you follow Healthcare Global Enterprises Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Healthcare Global Enterprises Limited

Guides on how to read this kind of business and the numbers that matter.